Full Product Details
Author: Gautam Sethi, PhD (Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore, Singapore) ,
Arun Kumar Singh (Assistant Professor, Department of Pharmacy, Vivekanand Global University Jaipur Rajasthan, India) ,
Hitesh Chopra, Ph.D. (Saveetha School of Engineering, India) ,
Milad Ashrafizadeh, PhD (Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, Turkey)
Publisher: Elsevier Science Publishing Co Inc
Imprint: Academic Press Inc
ISBN: 9780443336690
ISBN 10: 0443336695
Pages: 325
Publication Date: 05 January 2026
Audience:
Professional and scholarly
,
College/higher education
,
Professional & Vocational
,
Postgraduate, Research & Scholarly
Format: Paperback
Publisher's Status: Active
Availability: In Print
This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us.
Author Information
Dr. Gautam Sethi is a tenured Associate Professor in Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore. The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of oncogenic transcription factors by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. The findings of his research work have so far resulted several publications in high impact factor peer reviewed journals and many international awards. He also serves as an editorial board member for over more than 15 international journals Arun Kumar Singh completed his Master of Pharmacy (M. Pharm) in Pharmaceutics from Galgotias University, Greater Noida, India. He is currently an Assistant Professor in the Department of Pharmacy at Vivekanand Global University, where he is actively engaged in teaching and research. His research interests encompass various emerging and interdisciplinary fields, including nano-formulation, blockchain technology, the Internet of Things (IoT), machine learning, cancer biology, artificial intelligence, big data analytics, and neuroscience. Demonstrating a strong commitment to academic excellence, Mr. Singh has made significant contributions to the scientific community. Dr. Hitesh Chopra, PhD currently at Saveetha School of Engineering is working in primarily area of interest includes nanoformulations, natural polymers, cancer, and wound healing and metabolic disorders. He has authored several papers in high-repute journals with total impact factor more than 1000 Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors. Dr. Amir Reza Aref is a scientist at the Belfer Center of Applied Cancer Science, within the Dana-Farber Cancer Institute at Harvard Medical School. He made the important discovery in that it is possible to culture primary tumors in a novel 3D microfluidic system, by digesting them with collagenase and capturing spheroids that are composed of a mixture of tumor and immune cells. In addition, he has demonstrated the ability to treat these tumor spheroids with small molecule inhibitors and measure cytokine responses by collecting conditioned media from the device. This innovative technology is a major advance upon traditional 2D cell line culture and even organoid systems, which require time to establish and lack the immune microenvironment. Furthermore, it enables tumor cytokine profiling in a way not previously possible. Prior to joining the Belfer, he was an Instructor and a research fellow in the Medical Oncology Division at Harvard Medical School, where he characterized Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit in lung tumorigenesis which was resulted to start a new clinical trial at DFCI under supervision of Dr. David Barbie in 2015. He has also completed his post-doctoral in the Biological Engineering Department at MIT between 2009 and 11.
